NIBEC Co. Ltd (138610) - Net Assets
Based on the latest financial reports, NIBEC Co. Ltd (138610) has net assets worth ₩45.82 Billion KRW (≈ $31.05 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩63.00 Billion ≈ $42.70 Million USD) and total liabilities (₩17.18 Billion ≈ $11.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NIBEC Co. Ltd asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩45.82 Billion |
| % of Total Assets | 72.73% |
| Annual Growth Rate | 22.14% |
| 5-Year Change | 67.58% |
| 10-Year Change | 365.62% |
| Growth Volatility | 54.24 |
NIBEC Co. Ltd - Net Assets Trend (2014–2025)
This chart illustrates how NIBEC Co. Ltd's net assets have evolved over time, based on quarterly financial data. Also explore NIBEC Co. Ltd balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for NIBEC Co. Ltd (2014–2025)
The table below shows the annual net assets of NIBEC Co. Ltd from 2014 to 2025. For live valuation and market cap data, see 138610 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩45.82 Billion ≈ $31.05 Million |
+42.17% |
| 2024-12-31 | ₩32.23 Billion ≈ $21.84 Million |
+11.75% |
| 2023-12-31 | ₩28.84 Billion ≈ $19.55 Million |
-21.62% |
| 2022-12-31 | ₩36.80 Billion ≈ $24.94 Million |
+34.58% |
| 2021-12-31 | ₩27.34 Billion ≈ $18.53 Million |
-14.12% |
| 2020-12-31 | ₩31.84 Billion ≈ $21.58 Million |
+16.18% |
| 2019-12-31 | ₩27.40 Billion ≈ $18.57 Million |
+159.12% |
| 2018-12-31 | ₩10.58 Billion ≈ $7.17 Million |
-14.45% |
| 2017-12-31 | ₩12.36 Billion ≈ $8.38 Million |
+25.61% |
| 2016-12-31 | ₩9.84 Billion ≈ $6.67 Million |
-9.03% |
| 2015-12-31 | ₩10.82 Billion ≈ $7.33 Million |
+113.00% |
| 2014-12-31 | ₩5.08 Billion ≈ $3.44 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to NIBEC Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4020084911000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ₩96.81 Billion | 211.27% |
| Total Equity | ₩45.82 Billion | 100.00% |
NIBEC Co. Ltd Competitors by Market Cap
The table below lists competitors of NIBEC Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Asia Sermkij Leasing Public Company Limited
BK:ASK
|
$198.53 Million |
|
Siward Crystal Technology Co Ltd
TW:2484
|
$198.65 Million |
|
PAMT CORP
NASDAQ:PAMT
|
$198.76 Million |
|
Pyridam Farma Tbk
JK:PYFA
|
$198.84 Million |
|
Josef Manner & Comp. AG
VI:MAN
|
$198.45 Million |
|
Loandepot Inc
NYSE:LDI
|
$198.44 Million |
|
China Ecotek Corp
TW:1535
|
$198.44 Million |
|
Sajodaerim
KO:003960
|
$198.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in NIBEC Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 32,230,984,230 to 45,822,995,100, a change of 13,592,010,870 (42.2%).
- Net income of 4,641,985,400 contributed positively to equity growth.
- New share issuances of 105,000,000 increased equity.
- Other factors increased equity by 8,845,025,470.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩4.64 Billion | +10.13% |
| Share Issuances | ₩105.00 Million | +0.23% |
| Other Changes | ₩8.85 Billion | +19.3% |
| Total Change | ₩- | 42.17% |
Book Value vs Market Value Analysis
This analysis compares NIBEC Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.92x to 6.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩1530.75 | ₩25900.00 | x |
| 2017-12-31 | ₩1738.26 | ₩25900.00 | x |
| 2018-12-31 | ₩1403.65 | ₩25900.00 | x |
| 2019-12-31 | ₩2767.25 | ₩25900.00 | x |
| 2020-12-31 | ₩3215.10 | ₩25900.00 | x |
| 2021-12-31 | ₩2761.21 | ₩25900.00 | x |
| 2022-12-31 | ₩3695.72 | ₩25900.00 | x |
| 2023-12-31 | ₩2896.63 | ₩25900.00 | x |
| 2024-12-31 | ₩2958.84 | ₩25900.00 | x |
| 2025-12-31 | ₩4052.27 | ₩25900.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently NIBEC Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.13%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.19%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 1.37x
- Recent ROE (10.13%) is above the historical average (-23.14%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -71.29% | -75.65% | 0.34x | 2.79x | ₩-4.13 Billion |
| 2015 | -22.42% | -58.13% | 0.21x | 1.80x | ₩-3.51 Billion |
| 2016 | -30.76% | -63.01% | 0.21x | 2.33x | ₩-4.01 Billion |
| 2017 | -20.77% | -40.74% | 0.24x | 2.08x | ₩-3.80 Billion |
| 2018 | -39.20% | -79.61% | 0.23x | 2.11x | ₩-5.20 Billion |
| 2019 | -9.95% | -29.36% | 0.26x | 1.30x | ₩-5.47 Billion |
| 2020 | -11.43% | -57.22% | 0.12x | 1.67x | ₩-6.82 Billion |
| 2021 | -20.99% | -42.13% | 0.26x | 1.95x | ₩-8.47 Billion |
| 2022 | -10.23% | -17.38% | 0.29x | 2.04x | ₩-7.45 Billion |
| 2023 | -21.79% | -40.02% | 0.24x | 2.32x | ₩-9.17 Billion |
| 2024 | -28.94% | -37.99% | 0.39x | 1.94x | ₩-12.55 Billion |
| 2025 | 10.13% | 14.19% | 0.52x | 1.37x | ₩59.69 Million |
Industry Comparison
This section compares NIBEC Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $368,573,438,392
- Average return on equity (ROE) among peers: 0.96%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| NIBEC Co. Ltd (138610) | ₩45.82 Billion | -71.29% | 0.37x | $198.48 Million |
| ORIENTBIO Inc. (002630) | $57.60 Billion | 0.00% | 0.70x | $43.15 Million |
| Green Cross (005250) | $1.51 Trillion | 0.20% | 0.84x | $425.10 Million |
| Green Cross Holdings Preference Shares (005257) | $1.85 Trillion | 1.30% | 0.98x | $3.74 Million |
| Pharmicell (005690) | $51.52 Billion | 8.44% | 0.23x | $736.42 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $49.94 Million |
| HLB Co. Ltd (028300) | $19.44 Billion | 0.00% | 0.66x | $5.41 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $37.00 Billion | 2.34% | 0.69x | $19.29 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $37.92 Million |
| Hyundai Bioscience Co. Ltd (048410) | $58.24 Billion | 3.27% | 0.77x | $872.13 Million |
| iNtRON Biotechnology Inc (048530) | $11.93 Billion | -9.93% | 0.65x | $77.34 Million |
About NIBEC Co. Ltd
NIBEC Co., Ltd., a healthcare company, engages in the manufacture and sale of dental bone grafts and tissue regenerative collagen products in South Korea and internationally. It offers dental ointment, peptide containing dental bone graft materials, regenerative biomaterials, tooth whitening, tooth desensitizer, herbal toothpaste, and cosmetic products. The company was founded in 2000 and is base… Read more